X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-09-11 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $44.46 | -125,000 | 289,414 | -30% | -$5,557,754 | |||||
| M | 2025-09-11 | PASG | Passage Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $6.99 | +32,008 | 1,215,725 | +3% | +$223,735 | |||||
2025-09-11 | CDTX | Cidara Therapeutics, Inc. | Davarpanah Nicole Negar | Chief Medical Officer | S - Sale | $62.86 | -474 | 31,418 | -1% | -$29,797 | ||||||
| M | 2025-09-11 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.73 | -984,805 | 33,228,487 | -3% | -$1,703,971 | |||||
2025-09-11 | CGON | Cg Oncology, Inc. | Liu Brian Guan-Chyun | Dir | P - Purchase | $33.00 | +1,515,151 | 1,515,151 | New | +$49,999,983 | ||||||
| D | 2025-09-10 | TIL | Instil Bio, Inc. | Laumas Sandeep | CFO, CBO | S - Sale+OE | $23.39 | -30,000 | 0 | -100% | -$701,667 | |||||
2025-09-10 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $10.02 | -7,734 | 244,597 | -3% | -$77,495 | ||||||
| D | 2025-09-10 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.71 | -100,000 | 954,229 | -9% | -$471,000 | |||||
| D | 2025-09-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $3.23 | -200,000 | 1,006,439 | -17% | -$646,000 | |||||
| DM | 2025-09-10 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $36.20 | -50,419 | 0 | -100% | -$1,824,967 | |||||
| D | 2025-09-10 | HALO | Halozyme Therapeutics, Inc. | Labrosse Nicole | SVP, CFO | S - Sale+OE | $75.71 | -20,000 | 24,306 | -45% | -$1,514,267 | |||||
| D | 2025-09-10 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $120.52 | -29,111 | 100,743 | -22% | -$3,508,389 | |||||
| M | 2025-09-08 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.95 | -1,263,647 | 34,213,292 | -4% | -$2,457,975 | |||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.50 | -263 | 405,423 | 0% | -$132 | ||||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.50 | -488 | 3,268,909 | 0% | -$244 | ||||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.50 | -539 | 484,281 | 0% | -$270 | ||||||
2025-09-08 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $57.00 | -27,116 | 153,778 | -15% | -$1,545,612 | ||||||
| A | 2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.67 | -1,115 | 220,058 | -1% | -$5,205 | |||||
| M | 2025-09-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Henry Christian O | Dir | S - Sale | $10.99 | -20,000 | 24,310 | -45% | -$219,800 | |||||
2025-09-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $25.76 | -269 | 103,037 | 0% | -$6,929 | ||||||
2025-09-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $25.76 | -892 | 124,837 | -1% | -$22,978 | ||||||
| D | 2025-09-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $25.76 | -2,265 | 634,740 | 0% | -$58,346 | |||||
2025-09-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $25.76 | -235 | 48,454 | 0% | -$6,054 | ||||||
| D | 2025-09-05 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $31.53 | -27,015 | 0 | -100% | -$851,797 | |||||
2025-09-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $37.87 | -2,725 | 233,548 | -1% | -$103,198 | ||||||
| M | 2025-09-03 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.97 | -1,407,628 | 35,476,939 | -4% | -$2,767,982 | |||||
| DM | 2025-09-02 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $40.10 | -10,000 | 113,314 | -8% | -$400,992 | |||||
| DM | 2025-09-02 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $74.08 | -60,000 | 733,719 | -8% | -$4,444,626 | |||||
2025-09-03 | CGON | Cg Oncology, Inc. | Song Hong Fang | Dir | S - Sale | $27.80 | -100,000 | 7,039,077 | -1% | -$2,779,542 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $2.50 | -5,910 | 103,448 | -5% | -$14,756 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Principal Financial Officer | S - Sale | $2.50 | -15,842 | 346,570 | -4% | -$39,554 | ||||||
| D | 2025-09-03 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -1,000 | 0 | -100% | -$28,000 | |||||
2025-09-02 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $2.50 | -23,638 | 543,339 | -4% | -$59,019 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $2.50 | -51,562 | 6,280,595 | -1% | -$128,740 | ||||||
2025-09-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.60 | -710 | 69,490 | -1% | -$1,843 | ||||||
2025-09-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.60 | -458 | 16,369 | -3% | -$1,189 | ||||||
2025-09-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.60 | -5,592 | 274,690 | -2% | -$14,517 | ||||||
2025-09-04 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $8.92 | -10,000 | 51,086 | -16% | -$89,200 | ||||||
2025-09-02 | ADAP | Adaptimmune Therapeutics Plc | Wood Gavin | CFO | S - Sale | $0.01 | -96,000 | 0 | -100% | -$950 | ||||||
| D | 2025-09-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $35.77 | -10,000 | 66,363 | -13% | -$357,700 | |||||
2025-09-02 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $4.99 | -22,000 | 1,254,391 | -2% | -$109,811 | ||||||
2025-09-02 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $73.68 | -4,000 | 46,952 | -8% | -$294,736 | ||||||
| D | 2025-09-02 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale+OE | $133.55 | -517 | 5,772 | -8% | -$69,045 | |||||
2025-08-28 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $0.01 | -207,000 | 986,352 | -17% | -$2,091 | ||||||
| M | 2025-08-27 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $2.01 | -1,417,998 | 36,884,567 | -4% | -$2,848,511 | |||||
2025-08-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $113.63 | -10,000 | 595,725 | -2% | -$1,136,300 | ||||||
| D | 2025-08-26 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.84 | -100,000 | 954,229 | -9% | -$484,000 | |||||
2025-08-26 | ALEC | Alector, Inc. | Hammond Paula | Dir | S - Sale | $2.36 | -14,000 | 74,909 | -16% | -$32,998 | ||||||
| M | 2025-08-25 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $2.10 | -671,536 | 38,302,565 | -2% | -$1,411,083 | |||||
| D | 2025-08-25 | TECH | Bio-Techne Corp | Nusse Roeland | Dir | S - Sale+OE | $56.36 | -17,040 | 44,559 | -28% | -$960,388 | |||||
| D | 2025-08-25 | TECH | Bio-Techne Corp | Baumgartner Robert V | Dir | S - Sale+OE | $56.21 | -17,040 | 44,863 | -28% | -$957,818 | |||||
2025-08-25 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $27.69 | -853 | 48,689 | -2% | -$23,620 | ||||||
| M | 2025-08-22 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $39.47 | -188,094 | 3,017,166 | -6% | -$7,423,920 | |||||
| D | 2025-08-22 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $12.40 | -310 | 11,112 | -3% | -$3,843 | |||||
| D | 2025-08-21 | CLDI | Calidi Biotherapeutics, Inc. | Schoeneck James A | Dir | P - Purchase | $2.00 | +75,000 | 84,514 | +788% | +$150,000 | |||||
| D | 2025-08-21 | CLDI | Calidi Biotherapeutics, Inc. | Poma Eric E | CEO | P - Purchase | $2.00 | +25,000 | 25,000 | New | +$50,000 | |||||
| D | 2025-08-21 | CLDI | Calidi Biotherapeutics, Inc. | Leftwich Scott | Dir | P - Purchase | $2.00 | +125,000 | 146,631 | +578% | +$250,000 | |||||
| D | 2025-08-21 | CLDI | Calidi Biotherapeutics, Inc. | Jackson Andrew C. | CFO | P - Purchase | $2.00 | +2,500 | 2,500 | New | +$5,000 | |||||
| D | 2025-08-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $25.96 | -2,716 | 637,005 | 0% | -$70,518 | |||||
2025-08-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $25.96 | -238 | 49,542 | 0% | -$6,179 | ||||||
2025-08-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $25.96 | -619 | 125,729 | 0% | -$16,072 | ||||||
2025-08-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $25.96 | -918 | 102,917 | -1% | -$23,835 | ||||||
2025-08-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $25.96 | -1,840 | 233,529 | -1% | -$47,774 | ||||||
2025-08-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $25.96 | -521 | 103,306 | -1% | -$13,527 | ||||||
2025-08-22 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.83 | +700 | 168,762 | 0% | +$1,281 | ||||||
2025-08-20 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale | $296.99 | -1,267 | 7,313 | -15% | -$376,280 | ||||||
2025-08-21 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale | $2.85 | -57,054 | 1,165,289 | -5% | -$162,604 | ||||||
2025-08-21 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | CFO | S - Sale | $2.85 | -54,491 | 1,187,603 | -4% | -$155,299 | ||||||
2025-08-18 | ACOG | Alpha Cognition Inc. | Wills Robert James | Dir | P - Purchase | $8.49 | +15,000 | 15,000 | New | +$127,328 | ||||||
| M | 2025-08-18 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $1.67 | -2,241,045 | 1,392,091 | -62% | -$3,733,191 | |||||
| M | 2025-08-18 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $1.67 | -2,241,045 | 1,392,091 | -62% | -$3,733,191 | |||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Chief Technical Officer | S - Sale | $4.67 | -2,848 | 60,372 | -5% | -$13,294 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $4.67 | -542 | 62,556 | -1% | -$2,530 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $4.67 | -608 | 67,073 | -1% | -$2,838 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.67 | -2,735 | 220,058 | -1% | -$12,767 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $4.67 | -382 | 58,860 | -1% | -$1,783 | ||||||
2025-08-18 | ACOG | Alpha Cognition Inc. | Mertz Phillip Joseph | Dir | S - Sale | $9.00 | -27,778 | 35,022 | -44% | -$250,002 | ||||||
2025-08-18 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $11.62 | -2,958 | 67,889 | -4% | -$34,360 | ||||||
2025-08-18 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $11.61 | -1,809 | 35,258 | -5% | -$21,009 | ||||||
2025-08-18 | ACOG | Alpha Cognition Inc. | Mertz Leonard Powell | Dir | P - Purchase | $9.00 | +27,778 | 259,998 | +12% | +$250,002 | ||||||
2025-08-18 | VYGR | Voyager Therapeutics, Inc. | Ferguson Toby | Chief Medical Officer | S - Sale | $3.73 | -19,000 | 138,914 | -12% | -$70,870 | ||||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Chief Commercial Officer | S - Sale+OE | $0.60 | -49,656 | 59,344 | -46% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Duke William E. | CFO | S - Sale+OE | $0.60 | -49,656 | 49,344 | -50% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Green Julie | CHRO | S - Sale+OE | $0.60 | -49,656 | 49,344 | -50% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Andersen Jill | GC, Secretary | S - Sale+OE | $0.60 | -82,754 | 84,946 | -49% | -$49,677 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Allen Robert D. III | Chief Scientific Officer | S - Sale+OE | $0.60 | -45,932 | 53,068 | -46% | -$27,573 | |||||
2025-08-15 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $5.37 | -9,154 | 134,368 | -6% | -$49,157 | ||||||
2025-08-15 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | P - Purchase | $12.19 | +55,000 | 1,405,000 | +4% | +$670,423 | ||||||
| M | 2025-08-15 | ADAP | Adaptimmune Therapeutics Plc | Behbahani Ali | Dir | S - Sale | $0.01 | -19,500,000 | 0 | -100% | -$229,172 | |||||
2025-08-18 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | Chief R, D Commercial Officer | S - Sale | $5.52 | -36,599 | 668,197 | -5% | -$202,173 | ||||||
| M | 2025-08-15 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $39.34 | -260,713 | 3,205,260 | -8% | -$10,255,244 | |||||
2025-08-18 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $31.17 | -2,178 | 155,464 | -1% | -$67,880 | ||||||
| D | 2025-08-18 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $58.15 | -13,081 | 292,626 | -4% | -$760,660 | |||||
| M | 2025-07-17 | VXRT | Vaxart, Inc. | Finney Kevin | Dir | P - Purchase | $0.37 | +166,668 | 204,771 | +437% | +$61,934 | |||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $1.25 | -2,962 | 95,338 | -3% | -$3,711 | ||||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $1.25 | -5,053 | 172,803 | -3% | -$6,331 | ||||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $1.25 | -14,533 | 302,792 | -5% | -$18,210 | ||||||
| D | 2025-08-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $118.53 | -28,000 | 114,168 | -20% | -$3,318,927 | |||||
2025-08-15 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $2.73 | -25,500 | 382,221 | -6% | -$69,579 | ||||||
2025-08-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $118.53 | -2,500 | 160,110 | -2% | -$296,325 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |